Triglyceride lowering lipoprotein lipase enzyme and genetic Low Density Lipoprotein-C variants have been associated with reduced risk of coronary artery disease. It is found that Apoprotein-V variants strongly affect serum triglyceride levels. It is suggested that ApoA-V and LDL-C variants reduce triglyceride levels and prevent Coronary Artery Disease risk. If this is proven by further studies, Apo A-V will be a potential therapeutic target for CAD prevention.
References: Dorina Ibi et al; Journal of Lipid Research 2022, March 9.:100193